*To the Editor*:

Pulmonary arterial hypertension (PAH) is a severe disease with a poor prognosis, and both early diagnosis and early treatment are crucial to improve outcomes ([@bib1]). However, methods for early diagnosis are limited, especially at the stage of PAH development before the onset of elevated pulmonary arterial pressure. Macrophages play an important role in the development and progression of PAH ([@bib2]). In a recent study published in the *Journal*, Park and colleagues tracked macrophages in the lung using positron emission tomography (PET) with ^68^Ga-2-(p-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid mannosylated human serum albumin in patients with PAH and animal models ([@bib3]). Some of the results of these studies were previously reported in the form of an abstract ([@bib4]).

Via PET scans, Park and colleagues showed that the density of mannose receptor, a marker for macrophages, was significantly higher in patients with PAH and monocrotaline-induced rat PAH models ([@bib3]). In addition, pulmonary hypertension--targeted therapy with sildenafil or macitentan reduced the density of mannose receptor in the lungs of rats with PAH. These results suggest that the density of lung macrophage infiltration could reflect the severity of PAH. Interestingly, this study also indicates that at the early stage, only 1 week after injection of monocrotaline, a higher density of mannose receptor was found in the rat lungs. This suggests that using PET to monitor lung macrophages may predict the development of PAH even before the onset of high pulmonary arterial pressure, because in the first week after injection of monocrotaline, the rats showed only a mild elevation of pulmonary arterial pressure, which did not meet the standard for PAH diagnosis. Based on these results, Park and colleagues concluded that lung macrophage detection via PET scans could be used as a diagnostic and monitoring tool for PAH. However, this study raised several concerns. First, PAH is a rare disease, and PET is an expensive diagnostic approach with very limited availability; thus, it may not be realistic to use this technique to diagnose PAH in low-risk populations. However, in individuals at high risk for PAH, such as those with connective tissue disease or HIV infection, PET may be a useful approach for diagnosing PAH, especially at the early stage before the onset of elevated pulmonary arterial pressure. Second, the detection of mannose receptor to monitor macrophage infiltration is questionable because mannose receptor is expressed not only in macrophages but also in other cell types in the lung, especially tracheal smooth muscle cells ([@bib5]). It would be important to know whether this receptor is upregulated in macrophages in PAH before concluding that macrophage infiltration is increased in the lung during PAH, as the increased PET signal could be a result of increased mannose receptor expression, and not the number of macrophages. Third, the presence of an inflammatory lung disease, such as interstitial lung disease, may affect macrophage infiltration, as shown by Park and colleagues, which may affect diagnostic specificity.

Overall, this study is very interesting in that it demonstrates dynamic changes in mannose receptor in the lung at different time points of PAH development and therapy, and provides solid evidence that macrophage infiltration (mannose receptor elevation) is associated with PAH development and progression. Further studies, especially in humans, are needed to provide more data to evaluate the specificity and sensitivity of lung mannose receptor density for the diagnosis and evaluation of PAH.
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